Global Duchenne Muscular Dystrophy Drugs Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
Duchenne muscular dystrophy is an X-linked disease, which generally affects the male population. It is characterized by progressive muscle degeneration and weakness. The disease is caused due to mutations in the dystrophin gene, which result in the lack of production of dystrophin (a protein essential for maintaining healthy muscle function) in individuals. The lack of dystrophin weakens muscle function, causes loss of ambulation, harms the respiratory and cardiac function, and ultimately leads to death.
Scope of the Report:
This report focuses on the Duchenne Muscular Dystrophy Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The main symptoms of this condition appears in childhood and includes delay of motor functions; progressive muscle weakness; muscle contractures in legs; and muscle weakness in arms, neck, and more severely in the lower half of the body. The bones also develop peculiarly, causing skeletal deformities in the patient. Occurrences of pseudo-hypertrophy, cardiomyopathy, and breathing complications are some of the other symptoms of this condition.
The worldwide market for Duchenne Muscular Dystrophy Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
Chapter 1, to describe Duchenne Muscular Dystrophy Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Duchenne Muscular Dystrophy Drugs, with sales, revenue, and price of Duchenne Muscular Dystrophy Drugs, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Duchenne Muscular Dystrophy Drugs, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Duchenne Muscular Dystrophy Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Duchenne Muscular Dystrophy Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
Scope of the Report:
This report focuses on the Duchenne Muscular Dystrophy Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The main symptoms of this condition appears in childhood and includes delay of motor functions; progressive muscle weakness; muscle contractures in legs; and muscle weakness in arms, neck, and more severely in the lower half of the body. The bones also develop peculiarly, causing skeletal deformities in the patient. Occurrences of pseudo-hypertrophy, cardiomyopathy, and breathing complications are some of the other symptoms of this condition.
The worldwide market for Duchenne Muscular Dystrophy Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
- Akashi Therapeutics Inc
- Antisense Therapeutics Ltd
- Beech Tree Labs Inc
- Biogen Inc
- Bioleaders Corp
- BioMarin Pharmaceutical Inc
- Biophytis SAS
- Capricor Therapeutics Inc
- Catabasis Pharmaceuticals Inc
- CRISPR Therapeutics
- Cumberland Pharmaceuticals Inc
- Daiichi Sankyo Co Ltd
- Debiopharm International SA
- Editas Medicine Inc
- Eloxx Pharmaceuticals Inc
- F. Hoffmann-La Roche Ltd
- FibroGen Inc
- Fulcrum Therapeutics Inc
- Galapagos NV
- Genethon SA
- GTx Inc
- Santhera Pharmaceuticals Holding AG
- Sarepta Therapeutics Inc
- SOM Biotech SL
- Strykagen Corp
- Summit Therapeutics Plc
- Taiho Pharmaceutical Co Ltd
- Teijin Pharma Ltd
- WAVE Life Sciences Ltd
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
- Development & Drug Target
- Mechanism of Action (MoA)
- Route of Administration (RoA)
- Molecule Type
- Hospitals and Clinics
- Medical Laboratories
- Others
Chapter 1, to describe Duchenne Muscular Dystrophy Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Duchenne Muscular Dystrophy Drugs, with sales, revenue, and price of Duchenne Muscular Dystrophy Drugs, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Duchenne Muscular Dystrophy Drugs, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Duchenne Muscular Dystrophy Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Duchenne Muscular Dystrophy Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
1 MARKET OVERVIEW
1.1 Duchenne Muscular Dystrophy Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Development & Drug Target
1.2.2 Mechanism of Action (MoA)
1.2.3 Route of Administration (RoA)
1.2.4 Molecule Type
1.3 Market Analysis by Applications
1.3.1 Hospitals and Clinics
1.3.2 Medical Laboratories
1.3.3 Others
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 MANUFACTURERS PROFILES
2.1 Akashi Therapeutics Inc
2.1.1 Business Overview
2.1.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Akashi Therapeutics Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Antisense Therapeutics Ltd
2.2.1 Business Overview
2.2.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Antisense Therapeutics Ltd Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Beech Tree Labs Inc
2.3.1 Business Overview
2.3.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Beech Tree Labs Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Biogen Inc
2.4.1 Business Overview
2.4.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Biogen Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Bioleaders Corp
2.5.1 Business Overview
2.5.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Bioleaders Corp Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 BioMarin Pharmaceutical Inc
2.6.1 Business Overview
2.6.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 BioMarin Pharmaceutical Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 Biophytis SAS
2.7.1 Business Overview
2.7.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Biophytis SAS Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 Capricor Therapeutics Inc
2.8.1 Business Overview
2.8.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Capricor Therapeutics Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9 Catabasis Pharmaceuticals Inc
2.9.1 Business Overview
2.9.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Catabasis Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10 CRISPR Therapeutics
2.10.1 Business Overview
2.10.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 CRISPR Therapeutics Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.11 Cumberland Pharmaceuticals Inc
2.11.1 Business Overview
2.11.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Cumberland Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.12 Daiichi Sankyo Co Ltd
2.12.1 Business Overview
2.12.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 Daiichi Sankyo Co Ltd Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.13 Debiopharm International SA
2.13.1 Business Overview
2.13.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 Debiopharm International SA Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.14 Editas Medicine Inc
2.14.1 Business Overview
2.14.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.14.2.1 Product A
2.14.2.2 Product B
2.14.3 Editas Medicine Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.15 Eloxx Pharmaceuticals Inc
2.15.1 Business Overview
2.15.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.15.2.1 Product A
2.15.2.2 Product B
2.15.3 Eloxx Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.16 F. Hoffmann-La Roche Ltd
2.16.1 Business Overview
2.16.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.16.2.1 Product A
2.16.2.2 Product B
2.16.3 F. Hoffmann-La Roche Ltd Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.17 FibroGen Inc
2.17.1 Business Overview
2.17.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.17.2.1 Product A
2.17.2.2 Product B
2.17.3 FibroGen Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.18 Fulcrum Therapeutics Inc
2.18.1 Business Overview
2.18.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.18.2.1 Product A
2.18.2.2 Product B
2.18.3 Fulcrum Therapeutics Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.19 Galapagos NV
2.19.1 Business Overview
2.19.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.19.2.1 Product A
2.19.2.2 Product B
2.19.3 Galapagos NV Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.20 Genethon SA
2.20.1 Business Overview
2.20.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.20.2.1 Product A
2.20.2.2 Product B
2.20.3 Genethon SA Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.21 GTx Inc
2.21.1 Business Overview
2.2.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.21.2.1 Product A
2.21.2.2 Product B
2.21.3 GTx Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.22 Santhera Pharmaceuticals Holding AG
2.22.1 Business Overview
2.22.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.22.2.1 Product A
2.22.2.2 Product B
2.22.3 Santhera Pharmaceuticals Holding AG Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.23 Sarepta Therapeutics Inc
2.23.1 Business Overview
2.23.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.23.2.1 Product A
2.23.2.2 Product B
2.23.3 Sarepta Therapeutics Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.24 SOM Biotech SL
2.24.1 Business Overview
2.24.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.24.2.1 Product A
2.24.2.2 Product B
2.24.3 SOM Biotech SL Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.25 Strykagen Corp
2.25.1 Business Overview
2.25.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.25.2.1 Product A
2.25.2.2 Product B
2.25.3 Strykagen Corp Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.26 Summit Therapeutics Plc
2.26.1 Business Overview
2.26.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.26.2.1 Product A
2.26.2.2 Product B
2.26.3 Summit Therapeutics Plc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.27 Taiho Pharmaceutical Co Ltd
2.27.1 Business Overview
2.27.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.27.2.1 Product A
2.27.2.2 Product B
2.27.3 Taiho Pharmaceutical Co Ltd Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.28 Teijin Pharma Ltd
2.28.1 Business Overview
2.28.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.28.2.1 Product A
2.28.2.2 Product B
2.28.3 Teijin Pharma Ltd Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.29 WAVE Life Sciences Ltd
2.29.1 Business Overview
2.29.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.29.2.1 Product A
2.29.2.2 Product B
2.29.3 WAVE Life Sciences Ltd Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS SALES, REVENUE, MARKET SHARE AND COMPETITION BY MANUFACTURER (2016-2017)
3.1 Global Duchenne Muscular Dystrophy Drugs Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Duchenne Muscular Dystrophy Drugs Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Duchenne Muscular Dystrophy Drugs Manufacturer Market Share in 2017
3.3.2 Top 6 Duchenne Muscular Dystrophy Drugs Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET ANALYSIS BY REGIONS
4.1 Global Duchenne Muscular Dystrophy Drugs Sales, Revenue and Market Share by Regions
4.1.1 Global Duchenne Muscular Dystrophy Drugs Sales and Market Share by Regions (2013-2018)
4.1.2 Global Duchenne Muscular Dystrophy Drugs Revenue and Market Share by Regions (2013-2018)
4.2 North America Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
4.3 Europe Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
4.5 South America Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
5 NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS BY COUNTRIES
5.1 North America Duchenne Muscular Dystrophy Drugs Sales, Revenue and Market Share by Countries
5.1.1 North America Duchenne Muscular Dystrophy Drugs Sales and Market Share by Countries (2013-2018)
5.1.2 North America Duchenne Muscular Dystrophy Drugs Revenue and Market Share by Countries (2013-2018)
5.2 United States Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
5.3 Canada Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
5.4 Mexico Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
6 EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS BY COUNTRIES
6.1 Europe Duchenne Muscular Dystrophy Drugs Sales, Revenue and Market Share by Countries
6.1.1 Europe Duchenne Muscular Dystrophy Drugs Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Duchenne Muscular Dystrophy Drugs Revenue and Market Share by Countries (2013-2018)
6.2 Germany Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
6.3 UK Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
6.4 France Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
6.5 Russia Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
6.6 Italy Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
7 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS BY COUNTRIES
7.1 Asia-Pacific Duchenne Muscular Dystrophy Drugs Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Duchenne Muscular Dystrophy Drugs Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Duchenne Muscular Dystrophy Drugs Revenue and Market Share by Countries (2013-2018)
7.2 China Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
7.3 Japan Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
7.4 Korea Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
7.5 India Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
8 SOUTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS BY COUNTRIES
8.1 South America Duchenne Muscular Dystrophy Drugs Sales, Revenue and Market Share by Countries
8.1.1 South America Duchenne Muscular Dystrophy Drugs Sales and Market Share by Countries (2013-2018)
8.1.2 South America Duchenne Muscular Dystrophy Drugs Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
8.3 Argentina Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
8.4 Colombia Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
9 MIDDLE EAST AND AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS BY COUNTRIES
9.1 Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Duchenne Muscular Dystrophy Drugs Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
9.3 UAE Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
9.4 Egypt Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
9.5 Nigeria Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
9.6 South Africa Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
10 GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SEGMENT BY TYPE
10.1 Global Duchenne Muscular Dystrophy Drugs Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Duchenne Muscular Dystrophy Drugs Sales and Market Share by Type (2013-2018)
10.1.2 Global Duchenne Muscular Dystrophy Drugs Revenue and Market Share by Type (2013-2018)
10.2 Development & Drug Target Sales Growth and Price
10.2.1 Global Development & Drug Target Sales Growth (2013-2018)
10.2.2 Global Development & Drug Target Price (2013-2018)
10.3 Mechanism of Action (MoA) Sales Growth and Price
10.3.1 Global Mechanism of Action (MoA) Sales Growth (2013-2018)
10.3.2 Global Mechanism of Action (MoA) Price (2013-2018)
10.4 Route of Administration (RoA) Sales Growth and Price
10.4.1 Global Route of Administration (RoA) Sales Growth (2013-2018)
10.4.2 Global Route of Administration (RoA) Price (2013-2018)
10.5 Molecule Type Sales Growth and Price
10.5.1 Global Molecule Type Sales Growth (2013-2018)
10.5.2 Global Molecule Type Price (2013-2018)
11 GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SEGMENT BY APPLICATION
11.1 Global Duchenne Muscular Dystrophy Drugs Sales Market Share by Application (2013-2018)
11.2 Hospitals and Clinics Sales Growth (2013-2018)
11.3 Medical Laboratories Sales Growth (2013-2018)
11.4 Others Sales Growth (2013-2018)
12 DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET FORECAST (2018-2023)
12.1 Global Duchenne Muscular Dystrophy Drugs Sales, Revenue and Growth Rate (2018-2023)
12.2 Duchenne Muscular Dystrophy Drugs Market Forecast by Regions (2018-2023)
12.2.1 North America Duchenne Muscular Dystrophy Drugs Market Forecast (2018-2023)
12.2.2 Europe Duchenne Muscular Dystrophy Drugs Market Forecast (2018-2023)
12.2.3 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Forecast (2018-2023)
12.2.4 South America Duchenne Muscular Dystrophy Drugs Market Forecast (2018-2023)
12.2.5 Middle East and Africa Duchenne Muscular Dystrophy Drugs Market Forecast (2018-2023)
12.3 Duchenne Muscular Dystrophy Drugs Market Forecast by Type (2018-2023)
12.3.1 Global Duchenne Muscular Dystrophy Drugs Sales Forecast by Type (2018-2023)
12.3.2 Global Duchenne Muscular Dystrophy Drugs Market Share Forecast by Type (2018-2023)
12.4 Duchenne Muscular Dystrophy Drugs Market Forecast by Application (2018-2023)
12.4.1 Global Duchenne Muscular Dystrophy Drugs Sales Forecast by Application (2018-2023)
12.4.2 Global Duchenne Muscular Dystrophy Drugs Market Share Forecast by Application (2018-2023)
13 SALES CHANNEL, DISTRIBUTORS, TRADERS AND DEALERS
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 RESEARCH FINDINGS AND CONCLUSION
15 APPENDIX
15.1 Methodology
15.2 Data Source
1.1 Duchenne Muscular Dystrophy Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Development & Drug Target
1.2.2 Mechanism of Action (MoA)
1.2.3 Route of Administration (RoA)
1.2.4 Molecule Type
1.3 Market Analysis by Applications
1.3.1 Hospitals and Clinics
1.3.2 Medical Laboratories
1.3.3 Others
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 MANUFACTURERS PROFILES
2.1 Akashi Therapeutics Inc
2.1.1 Business Overview
2.1.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Akashi Therapeutics Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Antisense Therapeutics Ltd
2.2.1 Business Overview
2.2.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Antisense Therapeutics Ltd Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Beech Tree Labs Inc
2.3.1 Business Overview
2.3.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Beech Tree Labs Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Biogen Inc
2.4.1 Business Overview
2.4.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Biogen Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Bioleaders Corp
2.5.1 Business Overview
2.5.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Bioleaders Corp Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 BioMarin Pharmaceutical Inc
2.6.1 Business Overview
2.6.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 BioMarin Pharmaceutical Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 Biophytis SAS
2.7.1 Business Overview
2.7.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Biophytis SAS Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 Capricor Therapeutics Inc
2.8.1 Business Overview
2.8.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Capricor Therapeutics Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9 Catabasis Pharmaceuticals Inc
2.9.1 Business Overview
2.9.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Catabasis Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10 CRISPR Therapeutics
2.10.1 Business Overview
2.10.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 CRISPR Therapeutics Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.11 Cumberland Pharmaceuticals Inc
2.11.1 Business Overview
2.11.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Cumberland Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.12 Daiichi Sankyo Co Ltd
2.12.1 Business Overview
2.12.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 Daiichi Sankyo Co Ltd Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.13 Debiopharm International SA
2.13.1 Business Overview
2.13.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 Debiopharm International SA Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.14 Editas Medicine Inc
2.14.1 Business Overview
2.14.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.14.2.1 Product A
2.14.2.2 Product B
2.14.3 Editas Medicine Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.15 Eloxx Pharmaceuticals Inc
2.15.1 Business Overview
2.15.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.15.2.1 Product A
2.15.2.2 Product B
2.15.3 Eloxx Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.16 F. Hoffmann-La Roche Ltd
2.16.1 Business Overview
2.16.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.16.2.1 Product A
2.16.2.2 Product B
2.16.3 F. Hoffmann-La Roche Ltd Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.17 FibroGen Inc
2.17.1 Business Overview
2.17.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.17.2.1 Product A
2.17.2.2 Product B
2.17.3 FibroGen Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.18 Fulcrum Therapeutics Inc
2.18.1 Business Overview
2.18.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.18.2.1 Product A
2.18.2.2 Product B
2.18.3 Fulcrum Therapeutics Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.19 Galapagos NV
2.19.1 Business Overview
2.19.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.19.2.1 Product A
2.19.2.2 Product B
2.19.3 Galapagos NV Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.20 Genethon SA
2.20.1 Business Overview
2.20.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.20.2.1 Product A
2.20.2.2 Product B
2.20.3 Genethon SA Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.21 GTx Inc
2.21.1 Business Overview
2.2.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.21.2.1 Product A
2.21.2.2 Product B
2.21.3 GTx Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.22 Santhera Pharmaceuticals Holding AG
2.22.1 Business Overview
2.22.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.22.2.1 Product A
2.22.2.2 Product B
2.22.3 Santhera Pharmaceuticals Holding AG Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.23 Sarepta Therapeutics Inc
2.23.1 Business Overview
2.23.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.23.2.1 Product A
2.23.2.2 Product B
2.23.3 Sarepta Therapeutics Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.24 SOM Biotech SL
2.24.1 Business Overview
2.24.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.24.2.1 Product A
2.24.2.2 Product B
2.24.3 SOM Biotech SL Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.25 Strykagen Corp
2.25.1 Business Overview
2.25.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.25.2.1 Product A
2.25.2.2 Product B
2.25.3 Strykagen Corp Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.26 Summit Therapeutics Plc
2.26.1 Business Overview
2.26.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.26.2.1 Product A
2.26.2.2 Product B
2.26.3 Summit Therapeutics Plc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.27 Taiho Pharmaceutical Co Ltd
2.27.1 Business Overview
2.27.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.27.2.1 Product A
2.27.2.2 Product B
2.27.3 Taiho Pharmaceutical Co Ltd Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.28 Teijin Pharma Ltd
2.28.1 Business Overview
2.28.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.28.2.1 Product A
2.28.2.2 Product B
2.28.3 Teijin Pharma Ltd Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.29 WAVE Life Sciences Ltd
2.29.1 Business Overview
2.29.2 Duchenne Muscular Dystrophy Drugs Type and Applications
2.29.2.1 Product A
2.29.2.2 Product B
2.29.3 WAVE Life Sciences Ltd Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS SALES, REVENUE, MARKET SHARE AND COMPETITION BY MANUFACTURER (2016-2017)
3.1 Global Duchenne Muscular Dystrophy Drugs Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Duchenne Muscular Dystrophy Drugs Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Duchenne Muscular Dystrophy Drugs Manufacturer Market Share in 2017
3.3.2 Top 6 Duchenne Muscular Dystrophy Drugs Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET ANALYSIS BY REGIONS
4.1 Global Duchenne Muscular Dystrophy Drugs Sales, Revenue and Market Share by Regions
4.1.1 Global Duchenne Muscular Dystrophy Drugs Sales and Market Share by Regions (2013-2018)
4.1.2 Global Duchenne Muscular Dystrophy Drugs Revenue and Market Share by Regions (2013-2018)
4.2 North America Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
4.3 Europe Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
4.5 South America Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
5 NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS BY COUNTRIES
5.1 North America Duchenne Muscular Dystrophy Drugs Sales, Revenue and Market Share by Countries
5.1.1 North America Duchenne Muscular Dystrophy Drugs Sales and Market Share by Countries (2013-2018)
5.1.2 North America Duchenne Muscular Dystrophy Drugs Revenue and Market Share by Countries (2013-2018)
5.2 United States Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
5.3 Canada Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
5.4 Mexico Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
6 EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS BY COUNTRIES
6.1 Europe Duchenne Muscular Dystrophy Drugs Sales, Revenue and Market Share by Countries
6.1.1 Europe Duchenne Muscular Dystrophy Drugs Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Duchenne Muscular Dystrophy Drugs Revenue and Market Share by Countries (2013-2018)
6.2 Germany Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
6.3 UK Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
6.4 France Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
6.5 Russia Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
6.6 Italy Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
7 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS BY COUNTRIES
7.1 Asia-Pacific Duchenne Muscular Dystrophy Drugs Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Duchenne Muscular Dystrophy Drugs Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Duchenne Muscular Dystrophy Drugs Revenue and Market Share by Countries (2013-2018)
7.2 China Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
7.3 Japan Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
7.4 Korea Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
7.5 India Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
8 SOUTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS BY COUNTRIES
8.1 South America Duchenne Muscular Dystrophy Drugs Sales, Revenue and Market Share by Countries
8.1.1 South America Duchenne Muscular Dystrophy Drugs Sales and Market Share by Countries (2013-2018)
8.1.2 South America Duchenne Muscular Dystrophy Drugs Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
8.3 Argentina Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
8.4 Colombia Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
9 MIDDLE EAST AND AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS BY COUNTRIES
9.1 Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Duchenne Muscular Dystrophy Drugs Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
9.3 UAE Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
9.4 Egypt Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
9.5 Nigeria Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
9.6 South Africa Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
10 GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SEGMENT BY TYPE
10.1 Global Duchenne Muscular Dystrophy Drugs Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Duchenne Muscular Dystrophy Drugs Sales and Market Share by Type (2013-2018)
10.1.2 Global Duchenne Muscular Dystrophy Drugs Revenue and Market Share by Type (2013-2018)
10.2 Development & Drug Target Sales Growth and Price
10.2.1 Global Development & Drug Target Sales Growth (2013-2018)
10.2.2 Global Development & Drug Target Price (2013-2018)
10.3 Mechanism of Action (MoA) Sales Growth and Price
10.3.1 Global Mechanism of Action (MoA) Sales Growth (2013-2018)
10.3.2 Global Mechanism of Action (MoA) Price (2013-2018)
10.4 Route of Administration (RoA) Sales Growth and Price
10.4.1 Global Route of Administration (RoA) Sales Growth (2013-2018)
10.4.2 Global Route of Administration (RoA) Price (2013-2018)
10.5 Molecule Type Sales Growth and Price
10.5.1 Global Molecule Type Sales Growth (2013-2018)
10.5.2 Global Molecule Type Price (2013-2018)
11 GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SEGMENT BY APPLICATION
11.1 Global Duchenne Muscular Dystrophy Drugs Sales Market Share by Application (2013-2018)
11.2 Hospitals and Clinics Sales Growth (2013-2018)
11.3 Medical Laboratories Sales Growth (2013-2018)
11.4 Others Sales Growth (2013-2018)
12 DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET FORECAST (2018-2023)
12.1 Global Duchenne Muscular Dystrophy Drugs Sales, Revenue and Growth Rate (2018-2023)
12.2 Duchenne Muscular Dystrophy Drugs Market Forecast by Regions (2018-2023)
12.2.1 North America Duchenne Muscular Dystrophy Drugs Market Forecast (2018-2023)
12.2.2 Europe Duchenne Muscular Dystrophy Drugs Market Forecast (2018-2023)
12.2.3 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Forecast (2018-2023)
12.2.4 South America Duchenne Muscular Dystrophy Drugs Market Forecast (2018-2023)
12.2.5 Middle East and Africa Duchenne Muscular Dystrophy Drugs Market Forecast (2018-2023)
12.3 Duchenne Muscular Dystrophy Drugs Market Forecast by Type (2018-2023)
12.3.1 Global Duchenne Muscular Dystrophy Drugs Sales Forecast by Type (2018-2023)
12.3.2 Global Duchenne Muscular Dystrophy Drugs Market Share Forecast by Type (2018-2023)
12.4 Duchenne Muscular Dystrophy Drugs Market Forecast by Application (2018-2023)
12.4.1 Global Duchenne Muscular Dystrophy Drugs Sales Forecast by Application (2018-2023)
12.4.2 Global Duchenne Muscular Dystrophy Drugs Market Share Forecast by Application (2018-2023)
13 SALES CHANNEL, DISTRIBUTORS, TRADERS AND DEALERS
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 RESEARCH FINDINGS AND CONCLUSION
15 APPENDIX
15.1 Methodology
15.2 Data Source
LIST OF TABLES AND FIGURES
Figure Duchenne Muscular Dystrophy Drugs Picture
Table Product Specifications of Duchenne Muscular Dystrophy Drugs
Figure Global Sales Market Share of Duchenne Muscular Dystrophy Drugs by Types in 2017
Table Duchenne Muscular Dystrophy Drugs Types for Major Manufacturers
Figure Development & Drug Target Picture
Figure Mechanism of Action (MoA) Picture
Figure Route of Administration (RoA) Picture
Figure Molecule Type Picture
Figure Duchenne Muscular Dystrophy Drugs Sales Market Share by Applications in 2017
Figure Hospitals and Clinics Picture
Figure Medical Laboratories Picture
Figure Others Picture
Figure United States Duchenne Muscular Dystrophy Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Canada Duchenne Muscular Dystrophy Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Mexico Duchenne Muscular Dystrophy Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Germany Duchenne Muscular Dystrophy Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure France Duchenne Muscular Dystrophy Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure UK Duchenne Muscular Dystrophy Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Russia Duchenne Muscular Dystrophy Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Italy Duchenne Muscular Dystrophy Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure China Duchenne Muscular Dystrophy Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Japan Duchenne Muscular Dystrophy Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Korea Duchenne Muscular Dystrophy Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure India Duchenne Muscular Dystrophy Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Southeast Asia Duchenne Muscular Dystrophy Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Brazil Duchenne Muscular Dystrophy Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Egypt Duchenne Muscular Dystrophy Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Saudi Arabia Duchenne Muscular Dystrophy Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure South Africa Duchenne Muscular Dystrophy Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Nigeria Duchenne Muscular Dystrophy Drugs Revenue (Value) and Growth Rate (2013-2023)
Table Akashi Therapeutics Inc Basic Information, Manufacturing Base and Competitors
Table Akashi Therapeutics Inc Duchenne Muscular Dystrophy Drugs Type and Applications
Table Akashi Therapeutics Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Antisense Therapeutics Ltd Basic Information, Manufacturing Base and Competitors
Table Antisense Therapeutics Ltd Duchenne Muscular Dystrophy Drugs Type and Applications
Table Antisense Therapeutics Ltd Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Beech Tree Labs Inc Basic Information, Manufacturing Base and Competitors
Table Beech Tree Labs Inc Duchenne Muscular Dystrophy Drugs Type and Applications
Table Beech Tree Labs Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Biogen Inc Basic Information, Manufacturing Base and Competitors
Table Biogen Inc Duchenne Muscular Dystrophy Drugs Type and Applications
Table Biogen Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Bioleaders Corp Basic Information, Manufacturing Base and Competitors
Table Bioleaders Corp Duchenne Muscular Dystrophy Drugs Type and Applications
Table Bioleaders Corp Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table BioMarin Pharmaceutical Inc Basic Information, Manufacturing Base and Competitors
Table BioMarin Pharmaceutical Inc Duchenne Muscular Dystrophy Drugs Type and Applications
Table BioMarin Pharmaceutical Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Biophytis SAS Basic Information, Manufacturing Base and Competitors
Table Biophytis SAS Duchenne Muscular Dystrophy Drugs Type and Applications
Table Biophytis SAS Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Capricor Therapeutics Inc Basic Information, Manufacturing Base and Competitors
Table Capricor Therapeutics Inc Duchenne Muscular Dystrophy Drugs Type and Applications
Table Capricor Therapeutics Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Catabasis Pharmaceuticals Inc Basic Information, Manufacturing Base and Competitors
Table Catabasis Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Type and Applications
Table Catabasis Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table CRISPR Therapeutics Basic Information, Manufacturing Base and Competitors
Table CRISPR Therapeutics Duchenne Muscular Dystrophy Drugs Type and Applications
Table CRISPR Therapeutics Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Cumberland Pharmaceuticals Inc Basic Information, Manufacturing Base and Competitors
Table Cumberland Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Type and Applications
Table Cumberland Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Daiichi Sankyo Co Ltd Basic Information, Manufacturing Base and Competitors
Table Daiichi Sankyo Co Ltd Duchenne Muscular Dystrophy Drugs Type and Applications
Table Daiichi Sankyo Co Ltd Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Debiopharm International SA Basic Information, Manufacturing Base and Competitors
Table Debiopharm International SA Duchenne Muscular Dystrophy Drugs Type and Applications
Table Debiopharm International SA Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Editas Medicine Inc Basic Information, Manufacturing Base and Competitors
Table Editas Medicine Inc Duchenne Muscular Dystrophy Drugs Type and Applications
Table Editas Medicine Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Eloxx Pharmaceuticals Inc Basic Information, Manufacturing Base and Competitors
Table Eloxx Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Type and Applications
Table Eloxx Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table F. Hoffmann-La Roche Ltd Basic Information, Manufacturing Base and Competitors
Table F. Hoffmann-La Roche Ltd Duchenne Muscular Dystrophy Drugs Type and Applications
Table F. Hoffmann-La Roche Ltd Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table FibroGen Inc Basic Information, Manufacturing Base and Competitors
Table FibroGen Inc Duchenne Muscular Dystrophy Drugs Type and Applications
Table FibroGen Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Fulcrum Therapeutics Inc Basic Information, Manufacturing Base and Competitors
Table Fulcrum Therapeutics Inc Duchenne Muscular Dystrophy Drugs Type and Applications
Table Fulcrum Therapeutics Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Galapagos NV Basic Information, Manufacturing Base and Competitors
Table Galapagos NV Duchenne Muscular Dystrophy Drugs Type and Applications
Table Galapagos NV Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Genethon SA Basic Information, Manufacturing Base and Competitors
Table Genethon SA Duchenne Muscular Dystrophy Drugs Type and Applications
Table Genethon SA Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table GTx Inc Basic Information, Manufacturing Base and Competitors
Table GTx Inc Duchenne Muscular Dystrophy Drugs Type and Applications
Table GTx Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Santhera Pharmaceuticals Holding AG Basic Information, Manufacturing Base and Competitors
Table Santhera Pharmaceuticals Holding AG Duchenne Muscular Dystrophy Drugs Type and Applications
Table Santhera Pharmaceuticals Holding AG Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Sarepta Therapeutics Inc Basic Information, Manufacturing Base and Competitors
Table Sarepta Therapeutics Inc Duchenne Muscular Dystrophy Drugs Type and Applications
Table Sarepta Therapeutics Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table SOM Biotech SL Basic Information, Manufacturing Base and Competitors
Table SOM Biotech SL Duchenne Muscular Dystrophy Drugs Type and Applications
Table SOM Biotech SL Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Strykagen Corp Basic Information, Manufacturing Base and Competitors
Table Strykagen Corp Duchenne Muscular Dystrophy Drugs Type and Applications
Table Strykagen Corp Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Summit Therapeutics Plc Basic Information, Manufacturing Base and Competitors
Table Summit Therapeutics Plc Duchenne Muscular Dystrophy Drugs Type and Applications
Table Summit Therapeutics Plc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Taiho Pharmaceutical Co Ltd Basic Information, Manufacturing Base and Competitors
Table Taiho Pharmaceutical Co Ltd Duchenne Muscular Dystrophy Drugs Type and Applications
Table Taiho Pharmaceutical Co Ltd Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Teijin Pharma Ltd Basic Information, Manufacturing Base and Competitors
Table Teijin Pharma Ltd Duchenne Muscular Dystrophy Drugs Type and Applications
Table Teijin Pharma Ltd Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table WAVE Life Sciences Ltd Basic Information, Manufacturing Base and Competitors
Table WAVE Life Sciences Ltd Duchenne Muscular Dystrophy Drugs Type and Applications
Table WAVE Life Sciences Ltd Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Global Duchenne Muscular Dystrophy Drugs Sales by Manufacturer (2016-2017)
Figure Global Duchenne Muscular Dystrophy Drugs Sales Market Share by Manufacturer in 2016
Figure Global Duchenne Muscular Dystrophy Drugs Sales Market Share by Manufacturer in 2017
Table Global Duchenne Muscular Dystrophy Drugs Revenue by Manufacturer (2016-2017)
Figure Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Manufacturer in 2016
Figure Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Manufacturer in 2017
Figure Top 3 Duchenne Muscular Dystrophy Drugs Manufacturer (Revenue) Market Share in 2017
Figure Top 6 Duchenne Muscular Dystrophy Drugs Manufacturer (Revenue) Market Share in 2017
Figure Global Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure Global Duchenne Muscular Dystrophy Drugs Revenue and Growth Rate (2013-2018)
Table Global Duchenne Muscular Dystrophy Drugs Sales by Regions (2013-2018)
Table Global Duchenne Muscular Dystrophy Drugs Sales Market Share by Regions (2013-2018)
Table Global Duchenne Muscular Dystrophy Drugs Revenue by Regions (2013-2018)
Figure Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Regions in 2013
Figure Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Regions in 2017
Figure North America Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure Europe Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure Asia-Pacific Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure South America Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure North America Duchenne Muscular Dystrophy Drugs Revenue and Growth Rate (2013-2018)
Table North America Duchenne Muscular Dystrophy Drugs Sales by Countries (2013-2018)
Table North America Duchenne Muscular Dystrophy Drugs Sales Market Share by Countries (2013-2018)
Figure North America Duchenne Muscular Dystrophy Drugs Sales Market Share by Countries in 2013
Figure North America Duchenne Muscular Dystrophy Drugs Sales Market Share by Countries in 2017
Table North America Duchenne Muscular Dystrophy Drugs Revenue by Countries (2013-2018)
Table North America Duchenne Muscular Dystrophy Drugs Revenue Market Share by Countries (2013-2018)
Figure North America Duchenne Muscular Dystrophy Drugs Revenue Market Share by Countries in 2013
Figure North America Duchenne Muscular Dystrophy Drugs Revenue Market Share by Countries in 2017
Figure United States Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure Canada Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure Mexico Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure Europe Duchenne Muscular Dystrophy Drugs Revenue and Growth Rate (2013-2018)
Table Europe Duchenne Muscular Dystrophy Drugs Sales by Countries (2013-2018)
Table Europe Duchenne Muscular Dystrophy Drugs Sales Market Share by Countries (2013-2018)
Table Europe Duchenne Muscular Dystrophy Drugs Revenue by Countries (2013-2018)
Figure Europe Duchenne Muscular Dystrophy Drugs Revenue Market Share by Countries in 2016
Figure Europe Duchenne Muscular Dystrophy Drugs Revenue Market Share by Countries in 2017
Figure Germany Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure UK Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure France Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure Russia Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure Italy Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure Asia-Pacific Duchenne Muscular Dystrophy Drugs Revenue and Growth Rate (2013-2018)
Table Asia-Pacific Duchenne Muscular Dystrophy Drugs Sales by Countries (2013-2018)
Table Asia-Pacific Duchenne Muscular Dystrophy Drugs Sales Market Share by Countries (2013-2018)
Figure Asia-Pacific Duchenne Muscular Dystrophy Drugs Sales Market Share by Countries 2017
Table Asia-Pacific Duchenne Muscular Dystrophy Drugs Revenue by Countries (2013-2018)
Figure Asia-Pacific Duchenne Muscular Dystrophy Drugs Revenue Market Share by Countries 2017
Figure China Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure Japan Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure Korea Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure India Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure Southeast Asia Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure South America Duchenne Muscular Dystrophy Drugs Revenue and Growth Rate (2013-2018)
Table South America Duchenne Muscular Dystrophy Drugs Sales by Countries (2013-2018)
Table South America Duchenne Muscular Dystrophy Drugs Sales Market Share by Countries (2013-2018)
Figure South America Duchenne Muscular Dystrophy Drugs Sales Market Share by Countries in 2017
Table South America Duchenne Muscular Dystrophy Drugs Revenue by Countries (2013-2018)
Table South America Duchenne Muscular Dystrophy Drugs Revenue Market Share by Countries (2013-2018)
Figure South America Duchenne Muscular Dystrophy Drugs Revenue Market Share by Countries in 2017
Figure Brazil Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure Argentina Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure Colombia Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure Middle East and Africa Duchenne Muscular Dystrophy Drugs Revenue and Growth Rate (2013-2018)
Table Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales by Countries (2013-2018)
Table Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales Market Share by Countries (2013-2018)
Figure Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales Market Share by Countries in 2017
Table Middle East and Africa Duchenne Muscular Dystrophy Drugs Revenue by Countries (2013-2018)
Table Middle East and Africa Duchenne Muscular Dystrophy Drugs Revenue Market Share by Countries (2013-2018)
Figure Middle East and Africa Duchenne Muscular Dystrophy Drugs Revenue Market Share by Countries in 2013
Figure Middle East and Africa Duchenne Muscular Dystrophy Drugs Revenue Market Share by Countries in 2017
Figure Saudi Arabia Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure UAE Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure Egypt Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure Nigeria Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure South Africa Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Table Global Duchenne Muscular Dystrophy Drugs Sales by Type (2013-2018)
Table Global Duchenne Muscular Dystrophy Drugs Sales Share by Type (2013-2018)
Table Global Duchenne Muscular Dystrophy Drugs Revenue by Type (2013-2018)
Table Global Duchenne Muscular Dystrophy Drugs Revenue Share by Type (2013-2018)
Figure Global Development & Drug Target Sales Growth (2013-2018)
Figure Global Development & Drug Target Price (2013-2018)
Figure Global Mechanism of Action (MoA) Sales Growth (2013-2018)
Figure Global Mechanism of Action (MoA) Price (2013-2018)
Figure Global Route of Administration (RoA) Sales Growth (2013-2018)
Figure Global Route of Administration (RoA) Price (2013-2018)
Figure Global Molecule Type Sales Growth (2013-2018)
Figure Global Molecule Type Price (2013-2018)
Table Global Duchenne Muscular Dystrophy Drugs Sales by Application (2013-2018)
Table Global Duchenne Muscular Dystrophy Drugs Sales Share by Application (2013-2018)
Figure Global Medical Laboratories Sales Growth (2013-2018)
Figure Global Others Sales Growth (2013-2018)
Figure Global Duchenne Muscular Dystrophy Drugs Sales, Revenue and Growth Rate (2018-2023)
Table Global Duchenne Muscular Dystrophy Drugs Sales Forecast by Regions (2018-2023)
Table Global Duchenne Muscular Dystrophy Drugs Market Share Forecast by Regions (2018-2023)
Figure North America Sales Duchenne Muscular Dystrophy Drugs Market Forecast (2018-2023)
Figure Europe Sales Duchenne Muscular Dystrophy Drugs Market Forecast (2018-2023)
Figure Asia-Pacific Sales Duchenne Muscular Dystrophy Drugs Market Forecast (2018-2023)
Figure South America Sales Duchenne Muscular Dystrophy Drugs Market Forecast (2018-2023)
Figure Middle East and Africa Sales Duchenne Muscular Dystrophy Drugs Market Forecast (2018-2023)
Table Global Duchenne Muscular Dystrophy Drugs Sales Forecast by Type (2018-2023)
Table Global Duchenne Muscular Dystrophy Drugs Market Share Forecast by Type (2018-2023)
Table Global Duchenne Muscular Dystrophy Drugs Sales Forecast by Application (2018-2023)
Table Global Duchenne Muscular Dystrophy Drugs Market Share Forecast by Application (2018-2023)
Table Distributors/Traders/ Dealers List
Figure Duchenne Muscular Dystrophy Drugs Picture
Table Product Specifications of Duchenne Muscular Dystrophy Drugs
Figure Global Sales Market Share of Duchenne Muscular Dystrophy Drugs by Types in 2017
Table Duchenne Muscular Dystrophy Drugs Types for Major Manufacturers
Figure Development & Drug Target Picture
Figure Mechanism of Action (MoA) Picture
Figure Route of Administration (RoA) Picture
Figure Molecule Type Picture
Figure Duchenne Muscular Dystrophy Drugs Sales Market Share by Applications in 2017
Figure Hospitals and Clinics Picture
Figure Medical Laboratories Picture
Figure Others Picture
Figure United States Duchenne Muscular Dystrophy Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Canada Duchenne Muscular Dystrophy Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Mexico Duchenne Muscular Dystrophy Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Germany Duchenne Muscular Dystrophy Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure France Duchenne Muscular Dystrophy Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure UK Duchenne Muscular Dystrophy Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Russia Duchenne Muscular Dystrophy Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Italy Duchenne Muscular Dystrophy Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure China Duchenne Muscular Dystrophy Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Japan Duchenne Muscular Dystrophy Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Korea Duchenne Muscular Dystrophy Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure India Duchenne Muscular Dystrophy Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Southeast Asia Duchenne Muscular Dystrophy Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Brazil Duchenne Muscular Dystrophy Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Egypt Duchenne Muscular Dystrophy Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Saudi Arabia Duchenne Muscular Dystrophy Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure South Africa Duchenne Muscular Dystrophy Drugs Revenue (Value) and Growth Rate (2013-2023)
Figure Nigeria Duchenne Muscular Dystrophy Drugs Revenue (Value) and Growth Rate (2013-2023)
Table Akashi Therapeutics Inc Basic Information, Manufacturing Base and Competitors
Table Akashi Therapeutics Inc Duchenne Muscular Dystrophy Drugs Type and Applications
Table Akashi Therapeutics Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Antisense Therapeutics Ltd Basic Information, Manufacturing Base and Competitors
Table Antisense Therapeutics Ltd Duchenne Muscular Dystrophy Drugs Type and Applications
Table Antisense Therapeutics Ltd Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Beech Tree Labs Inc Basic Information, Manufacturing Base and Competitors
Table Beech Tree Labs Inc Duchenne Muscular Dystrophy Drugs Type and Applications
Table Beech Tree Labs Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Biogen Inc Basic Information, Manufacturing Base and Competitors
Table Biogen Inc Duchenne Muscular Dystrophy Drugs Type and Applications
Table Biogen Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Bioleaders Corp Basic Information, Manufacturing Base and Competitors
Table Bioleaders Corp Duchenne Muscular Dystrophy Drugs Type and Applications
Table Bioleaders Corp Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table BioMarin Pharmaceutical Inc Basic Information, Manufacturing Base and Competitors
Table BioMarin Pharmaceutical Inc Duchenne Muscular Dystrophy Drugs Type and Applications
Table BioMarin Pharmaceutical Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Biophytis SAS Basic Information, Manufacturing Base and Competitors
Table Biophytis SAS Duchenne Muscular Dystrophy Drugs Type and Applications
Table Biophytis SAS Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Capricor Therapeutics Inc Basic Information, Manufacturing Base and Competitors
Table Capricor Therapeutics Inc Duchenne Muscular Dystrophy Drugs Type and Applications
Table Capricor Therapeutics Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Catabasis Pharmaceuticals Inc Basic Information, Manufacturing Base and Competitors
Table Catabasis Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Type and Applications
Table Catabasis Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table CRISPR Therapeutics Basic Information, Manufacturing Base and Competitors
Table CRISPR Therapeutics Duchenne Muscular Dystrophy Drugs Type and Applications
Table CRISPR Therapeutics Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Cumberland Pharmaceuticals Inc Basic Information, Manufacturing Base and Competitors
Table Cumberland Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Type and Applications
Table Cumberland Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Daiichi Sankyo Co Ltd Basic Information, Manufacturing Base and Competitors
Table Daiichi Sankyo Co Ltd Duchenne Muscular Dystrophy Drugs Type and Applications
Table Daiichi Sankyo Co Ltd Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Debiopharm International SA Basic Information, Manufacturing Base and Competitors
Table Debiopharm International SA Duchenne Muscular Dystrophy Drugs Type and Applications
Table Debiopharm International SA Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Editas Medicine Inc Basic Information, Manufacturing Base and Competitors
Table Editas Medicine Inc Duchenne Muscular Dystrophy Drugs Type and Applications
Table Editas Medicine Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Eloxx Pharmaceuticals Inc Basic Information, Manufacturing Base and Competitors
Table Eloxx Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Type and Applications
Table Eloxx Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table F. Hoffmann-La Roche Ltd Basic Information, Manufacturing Base and Competitors
Table F. Hoffmann-La Roche Ltd Duchenne Muscular Dystrophy Drugs Type and Applications
Table F. Hoffmann-La Roche Ltd Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table FibroGen Inc Basic Information, Manufacturing Base and Competitors
Table FibroGen Inc Duchenne Muscular Dystrophy Drugs Type and Applications
Table FibroGen Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Fulcrum Therapeutics Inc Basic Information, Manufacturing Base and Competitors
Table Fulcrum Therapeutics Inc Duchenne Muscular Dystrophy Drugs Type and Applications
Table Fulcrum Therapeutics Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Galapagos NV Basic Information, Manufacturing Base and Competitors
Table Galapagos NV Duchenne Muscular Dystrophy Drugs Type and Applications
Table Galapagos NV Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Genethon SA Basic Information, Manufacturing Base and Competitors
Table Genethon SA Duchenne Muscular Dystrophy Drugs Type and Applications
Table Genethon SA Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table GTx Inc Basic Information, Manufacturing Base and Competitors
Table GTx Inc Duchenne Muscular Dystrophy Drugs Type and Applications
Table GTx Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Santhera Pharmaceuticals Holding AG Basic Information, Manufacturing Base and Competitors
Table Santhera Pharmaceuticals Holding AG Duchenne Muscular Dystrophy Drugs Type and Applications
Table Santhera Pharmaceuticals Holding AG Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Sarepta Therapeutics Inc Basic Information, Manufacturing Base and Competitors
Table Sarepta Therapeutics Inc Duchenne Muscular Dystrophy Drugs Type and Applications
Table Sarepta Therapeutics Inc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table SOM Biotech SL Basic Information, Manufacturing Base and Competitors
Table SOM Biotech SL Duchenne Muscular Dystrophy Drugs Type and Applications
Table SOM Biotech SL Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Strykagen Corp Basic Information, Manufacturing Base and Competitors
Table Strykagen Corp Duchenne Muscular Dystrophy Drugs Type and Applications
Table Strykagen Corp Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Summit Therapeutics Plc Basic Information, Manufacturing Base and Competitors
Table Summit Therapeutics Plc Duchenne Muscular Dystrophy Drugs Type and Applications
Table Summit Therapeutics Plc Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Taiho Pharmaceutical Co Ltd Basic Information, Manufacturing Base and Competitors
Table Taiho Pharmaceutical Co Ltd Duchenne Muscular Dystrophy Drugs Type and Applications
Table Taiho Pharmaceutical Co Ltd Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Teijin Pharma Ltd Basic Information, Manufacturing Base and Competitors
Table Teijin Pharma Ltd Duchenne Muscular Dystrophy Drugs Type and Applications
Table Teijin Pharma Ltd Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table WAVE Life Sciences Ltd Basic Information, Manufacturing Base and Competitors
Table WAVE Life Sciences Ltd Duchenne Muscular Dystrophy Drugs Type and Applications
Table WAVE Life Sciences Ltd Duchenne Muscular Dystrophy Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Global Duchenne Muscular Dystrophy Drugs Sales by Manufacturer (2016-2017)
Figure Global Duchenne Muscular Dystrophy Drugs Sales Market Share by Manufacturer in 2016
Figure Global Duchenne Muscular Dystrophy Drugs Sales Market Share by Manufacturer in 2017
Table Global Duchenne Muscular Dystrophy Drugs Revenue by Manufacturer (2016-2017)
Figure Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Manufacturer in 2016
Figure Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Manufacturer in 2017
Figure Top 3 Duchenne Muscular Dystrophy Drugs Manufacturer (Revenue) Market Share in 2017
Figure Top 6 Duchenne Muscular Dystrophy Drugs Manufacturer (Revenue) Market Share in 2017
Figure Global Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure Global Duchenne Muscular Dystrophy Drugs Revenue and Growth Rate (2013-2018)
Table Global Duchenne Muscular Dystrophy Drugs Sales by Regions (2013-2018)
Table Global Duchenne Muscular Dystrophy Drugs Sales Market Share by Regions (2013-2018)
Table Global Duchenne Muscular Dystrophy Drugs Revenue by Regions (2013-2018)
Figure Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Regions in 2013
Figure Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Regions in 2017
Figure North America Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure Europe Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure Asia-Pacific Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure South America Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure North America Duchenne Muscular Dystrophy Drugs Revenue and Growth Rate (2013-2018)
Table North America Duchenne Muscular Dystrophy Drugs Sales by Countries (2013-2018)
Table North America Duchenne Muscular Dystrophy Drugs Sales Market Share by Countries (2013-2018)
Figure North America Duchenne Muscular Dystrophy Drugs Sales Market Share by Countries in 2013
Figure North America Duchenne Muscular Dystrophy Drugs Sales Market Share by Countries in 2017
Table North America Duchenne Muscular Dystrophy Drugs Revenue by Countries (2013-2018)
Table North America Duchenne Muscular Dystrophy Drugs Revenue Market Share by Countries (2013-2018)
Figure North America Duchenne Muscular Dystrophy Drugs Revenue Market Share by Countries in 2013
Figure North America Duchenne Muscular Dystrophy Drugs Revenue Market Share by Countries in 2017
Figure United States Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure Canada Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure Mexico Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure Europe Duchenne Muscular Dystrophy Drugs Revenue and Growth Rate (2013-2018)
Table Europe Duchenne Muscular Dystrophy Drugs Sales by Countries (2013-2018)
Table Europe Duchenne Muscular Dystrophy Drugs Sales Market Share by Countries (2013-2018)
Table Europe Duchenne Muscular Dystrophy Drugs Revenue by Countries (2013-2018)
Figure Europe Duchenne Muscular Dystrophy Drugs Revenue Market Share by Countries in 2016
Figure Europe Duchenne Muscular Dystrophy Drugs Revenue Market Share by Countries in 2017
Figure Germany Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure UK Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure France Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure Russia Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure Italy Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure Asia-Pacific Duchenne Muscular Dystrophy Drugs Revenue and Growth Rate (2013-2018)
Table Asia-Pacific Duchenne Muscular Dystrophy Drugs Sales by Countries (2013-2018)
Table Asia-Pacific Duchenne Muscular Dystrophy Drugs Sales Market Share by Countries (2013-2018)
Figure Asia-Pacific Duchenne Muscular Dystrophy Drugs Sales Market Share by Countries 2017
Table Asia-Pacific Duchenne Muscular Dystrophy Drugs Revenue by Countries (2013-2018)
Figure Asia-Pacific Duchenne Muscular Dystrophy Drugs Revenue Market Share by Countries 2017
Figure China Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure Japan Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure Korea Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure India Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure Southeast Asia Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure South America Duchenne Muscular Dystrophy Drugs Revenue and Growth Rate (2013-2018)
Table South America Duchenne Muscular Dystrophy Drugs Sales by Countries (2013-2018)
Table South America Duchenne Muscular Dystrophy Drugs Sales Market Share by Countries (2013-2018)
Figure South America Duchenne Muscular Dystrophy Drugs Sales Market Share by Countries in 2017
Table South America Duchenne Muscular Dystrophy Drugs Revenue by Countries (2013-2018)
Table South America Duchenne Muscular Dystrophy Drugs Revenue Market Share by Countries (2013-2018)
Figure South America Duchenne Muscular Dystrophy Drugs Revenue Market Share by Countries in 2017
Figure Brazil Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure Argentina Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure Colombia Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure Middle East and Africa Duchenne Muscular Dystrophy Drugs Revenue and Growth Rate (2013-2018)
Table Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales by Countries (2013-2018)
Table Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales Market Share by Countries (2013-2018)
Figure Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales Market Share by Countries in 2017
Table Middle East and Africa Duchenne Muscular Dystrophy Drugs Revenue by Countries (2013-2018)
Table Middle East and Africa Duchenne Muscular Dystrophy Drugs Revenue Market Share by Countries (2013-2018)
Figure Middle East and Africa Duchenne Muscular Dystrophy Drugs Revenue Market Share by Countries in 2013
Figure Middle East and Africa Duchenne Muscular Dystrophy Drugs Revenue Market Share by Countries in 2017
Figure Saudi Arabia Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure UAE Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure Egypt Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure Nigeria Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Figure South Africa Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2013-2018)
Table Global Duchenne Muscular Dystrophy Drugs Sales by Type (2013-2018)
Table Global Duchenne Muscular Dystrophy Drugs Sales Share by Type (2013-2018)
Table Global Duchenne Muscular Dystrophy Drugs Revenue by Type (2013-2018)
Table Global Duchenne Muscular Dystrophy Drugs Revenue Share by Type (2013-2018)
Figure Global Development & Drug Target Sales Growth (2013-2018)
Figure Global Development & Drug Target Price (2013-2018)
Figure Global Mechanism of Action (MoA) Sales Growth (2013-2018)
Figure Global Mechanism of Action (MoA) Price (2013-2018)
Figure Global Route of Administration (RoA) Sales Growth (2013-2018)
Figure Global Route of Administration (RoA) Price (2013-2018)
Figure Global Molecule Type Sales Growth (2013-2018)
Figure Global Molecule Type Price (2013-2018)
Table Global Duchenne Muscular Dystrophy Drugs Sales by Application (2013-2018)
Table Global Duchenne Muscular Dystrophy Drugs Sales Share by Application (2013-2018)
Figure Global Medical Laboratories Sales Growth (2013-2018)
Figure Global Others Sales Growth (2013-2018)
Figure Global Duchenne Muscular Dystrophy Drugs Sales, Revenue and Growth Rate (2018-2023)
Table Global Duchenne Muscular Dystrophy Drugs Sales Forecast by Regions (2018-2023)
Table Global Duchenne Muscular Dystrophy Drugs Market Share Forecast by Regions (2018-2023)
Figure North America Sales Duchenne Muscular Dystrophy Drugs Market Forecast (2018-2023)
Figure Europe Sales Duchenne Muscular Dystrophy Drugs Market Forecast (2018-2023)
Figure Asia-Pacific Sales Duchenne Muscular Dystrophy Drugs Market Forecast (2018-2023)
Figure South America Sales Duchenne Muscular Dystrophy Drugs Market Forecast (2018-2023)
Figure Middle East and Africa Sales Duchenne Muscular Dystrophy Drugs Market Forecast (2018-2023)
Table Global Duchenne Muscular Dystrophy Drugs Sales Forecast by Type (2018-2023)
Table Global Duchenne Muscular Dystrophy Drugs Market Share Forecast by Type (2018-2023)
Table Global Duchenne Muscular Dystrophy Drugs Sales Forecast by Application (2018-2023)
Table Global Duchenne Muscular Dystrophy Drugs Market Share Forecast by Application (2018-2023)
Table Distributors/Traders/ Dealers List
